You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 35.175.0.0/16 has been blocked (disabled) by ‪JJMC89‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 05:20, 2 March 2025.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Jon Kolbert‬. The reason given is Open proxy/Webhost: See the help page if you are affected .
- Start of block: 05:38, 21 February 2024
- Expiry of block: 05:38, 21 February 2029
Your current IP address is 35.175.116.192. The blocked range is 35.175.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((short description|American biologist))
((Multiple issues|
((BLP sources|date=March 2020))
((Like resume|date=February 2023))
((Third-party|date=February 2023))
))
((Infobox person
| name               = 
| alma_mater         = [[University of California, Davis]]<br>[[Indiana University]]
| awards             = [[Lasker-DeBakey Clinical Medical Research Award]] (2019)
| known_for          = Co-development of Herceptin
))

'''H. Michael Shepard''' (born 1949) is an American [[cancer]] researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award, which he shared with [[Dennis Slamon]] and [[Axel Ullrich]] for their development of [[Herceptin]]<ref name="Lasker Foundation">((cite web|url=https://laskerfoundation.org/winners/2019-winners/|title=2019 Winners|date=2019|access-date=8 November 2021))</ref>

==Education and career==
Shepherd holds a bachelor's degree from the [[University of California, Davis]], and a Ph.D. from Indiana University. Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. His introduction to biotechnology came when he joined Genentech in 1980. Following Genentech, he has been a Founder or Principal in several biotech companies. These include Canji, Inc., NewBiotics, Receptor Biologix, and Halozyme.

==Development of Herceptin==
Following Ullrich's characterization of the HER2 protooncogene, Shepard collaborated with Ullrich and Slamon to explore possible links to breast cancer. Slamon discovered, along with other colleagues in the field, that HER2 overexpression in breast cancer predicts shorter survival. However, a lot of proteins are overexpressed in cancer cells and correlate with shorter survival. Therefore, the remaining question was: Is the overexpression of HER2 a significant driver in tumor progression and how does this work? Shepard and Hudziak discovered that too much HER2 made tumor cells grow better. Then made a key discovery about how HER2 can cause resistance to immune cell killing of tumor cells. Overexpression of HER2 makes cells resistant to killing by macrophages, which are the first line of defense against cancer. This work was done in collaboration with Dr. Hans Schreiber at the University of Chicago. Shepard and colleagues at Genentech (Paul Carter, Gail Lewis) then invented Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and developed it into a life-saving therapy for women with breast cancer. The innovation reduces the risk of recurrence and extends survival time for patients with metastatic as well as early-stage disease. Every year, more than 50,000 women in the US are diagnosed with the type of breast cancer that the drug attacks, and over 2.3 million individuals have received the treatment since it became available.

==Other activity==
Shepard has made seminal contributions to gene therapy of cancer, to tumor suppressor gene targeted small molecule therapeutics, and to drugs which target the tumor extracellular matrix. He continues his work, now expanding successful treatment paradigms used in cancer to approach inflammatory and autoimmune diseases. Shepard also consults for biopharma companies on how to develop meaningful biomarkers that will speed drug development. Education is another of Dr. Shepard's passions, and he gives lectures meant to teach, stimulate, excite and give hope to interested scientists and students, and to cancer patients who need to more about how the disease works. Dr. Shepard has co-authored many peer-reviewed publications and patents.

==Patents==

* ((US patent|7,138,388)) &mdash; ''Methods to treat autoimmune and inflammatory conditions''
* ((US patent|7,105,156)) &mdash; ''Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells''
* ((US patent|6,946,259)) &mdash; ''Compositions and methods for treating cells having double minute DNA''
* ((US patent|6,683,061)) &mdash; ''Enzyme catalyzed therapeutic activation''
* ((US patent|6,551,585)) &mdash; ''Use of tumor necrosis factor as an adjuvant''
* ((US patent|6,495,553)) &mdash; ''Methods and compositions for overcoming resistance to biologic and chemotherapy''
* ((US patent|6,399,063)) &mdash; ''Monoclonal antibodies directed to the HER2 receptor''
* ((US patent|6,387,371)) &mdash; ''Monoclonal antibodies directed to the HER2 receptor''
* ((US patent|6,348,352)) &mdash; ''Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene''
* ((US patent|6,339,151)) &mdash; ''Enzyme catalyzed therapeutic agents''
* ((US patent|6,333,169)) &mdash; ''HER2 extracellular domain''
* ((US patent|6,331,524)) &mdash; ''Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy''
* ((US patent|6,245,750)) &mdash; ''Enzyme catalyzed therapeutic agents''
* ((US patent|6,165,464)) &mdash; ''Monoclonal antibodies directed to the HER2 receptor''
* ((US patent|6,159,706)) &mdash; ''Application of enzyme prodrugs as anti-infective agents''
* ((US patent|6,015,567)) &mdash; ''HER2 extracellular domain''
* ((US patent|5,851,991)) &mdash; ''Therapeutic use of the retinoblastoma susceptibility gene product''
* ((US patent|5,837,520)) &mdash; ''Method of purification of viral vectors''
* ((US patent|5,772,997)) &mdash; ''Monoclonal antibodies directed to the HER2 receptor''
* ((US patent|5,720,954)) &mdash; ''Monoclonal antibodies directed to the HER2 receptor''
* ((US patent|5,710,255)) &mdash; ''Characterization of a novel anti-p110.sup.RB monoclonal antibody''
* ((US patent|5,677,171)) &mdash; ''Monoclonal antibodies directed to the HER2 receptor''
* ((US patent|4,963,354)) &mdash; ''Use of tumor necrosis factor (TNF) as an adjuvant''
* ((US patent|4,808,402)) &mdash; ''Method and compositions for modulating neovascularization''

==References==
((reflist))

==External links==
*[http://www.receptorbiologix.com/ Receptor Biologix]
*[https://web.archive.org/web/20081007160947/http://www.warrenalpert.org/event/ Alpert Foundation]

((authority control))

((DEFAULTSORT:Shepard, H. Michael))
[[Category:Living people]]
[[Category:American molecular biologists]]
[[Category:American oncologists]]
[[Category:Indiana University alumni]]
[[Category:University of California, Davis alumni]]
[[Category:1949 births]]

Pages transcluded onto the current version of this page (help):

H. Michael Shepard (edit)
Template:Ambox (view source) (template editor protected)
Template:Authority control (view source) (template editor protected)
Template:BLP sources (view source) (template editor protected)
Template:Br separated entries (view source) (template editor protected)
Template:Cite web (view source) (protected)
Template:Count (view source) (template editor protected)
Template:DMCA (view source) (template editor protected)
Template:Dated maintenance category (view source) (template editor protected)
Template:Dated maintenance category (articles) (view source) (template editor protected)
Template:Digits (view source) (template editor protected)
Template:FULLROOTPAGENAME (view source) (template editor protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:If empty (view source) (protected)
Template:Infobox person (view source) (template editor protected)
Template:Like resume (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:Multiple issues (view source) (template editor protected)
Template:Multiple issues/styles.css (view source) (template editor protected)
Template:Ns has subpages (view source) (protected)
Template:PAGENAMEBASE (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Plainlist/styles.css (view source) (protected)
Template:Pluralize from text (view source) (template editor protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:Replace (view source) (protected)
Template:Resume-like (view source) (template editor protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Third-party (view source) (template editor protected)
Template:US patent (view source) (template editor protected)
Template:Unbulleted list (view source) (template editor protected)
Template:Wikidata image (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Authority control (view source) (template editor protected)
Module:Authority control/config (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for clobbered parameters (view source) (template editor protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Detect singular (view source) (template editor protected)
Module:Disambiguation/templates (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:If empty (view source) (protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:List (view source) (protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Ns has subpages (view source) (protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:ParameterCount (view source) (template editor protected)
Module:SDcat (view source) (protected)
Module:Separated entries (view source) (protected)
Module:String (view source) (protected)
Module:TableTools (view source) (protected)
Module:Text (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to H. Michael Shepard.

Retrieved from "https://en.wikipedia.org/wiki/H._Michael_Shepard"